<DOC>
	<DOCNO>NCT01611623</DOCNO>
	<brief_summary>Hsp90 chemical body involved promotion cancer . SNX-5422 experimental drug block Hsp90 . It evaluate safety patient cancer .</brief_summary>
	<brief_title>Safety Pharmacology Study SNX-5422 Subjects With Refractory Solid Tumor Malignancies</brief_title>
	<detailed_description>Correlation observe Hsp90 client protein level change functional effect cell vitro study SNX-5422 , support inhibition Hsp90 mechanism action compound . SNX-5422 demonstrated significant antitumor activity mouse xenograft model human tumor , include breast ( BT474 , MX-1 ) , colon ( HT29 ) , prostate ( PC3 ) , melanoma ( A375 ) multiple oral dosing regimen . This study employ critical risk management feature include use NCI Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.03 , provide scale consistently grade severity AEs , toxicity criterion analyse dose escalation , frequent laboratory clinical observation , correlation AEs plasma concentration drug , monitor QTc interval appropriate time point , conservative dose-escalation scheme .</detailed_description>
	<criteria>&gt; 18 year old histologically confirm solid tumor malignancy refractory available therapy therapy available adequate organ function CNS malignancy significant GI disease risk prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Solid tumor malignancy</keyword>
	<keyword>Hsp90</keyword>
</DOC>